HIV-CORE 004
Status:Completed
Phase:I/II
Principal Investigator(s):Walter Jaoko
Objective:This study will evaluate safety and immunogencity of vaccines focusing T cell responses on the conserved region of the HIV-1 proteome.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionAd35-GRIN 5 x 10^10 vp IM at week 0, MVA.HIVconsv 2 x 10^8 pfu IM at week 8
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionpSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionElectroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8.
Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
NCT02099994
Trial Sponsors:
EDCTP, IAVI, Ichor Medical Systems Inc., Karolinska Institutet, University of Nairobi, University of Oxford
Start Date
End Date
March 31, 2014
February 29, 2016
Enrollment:72
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Cisgender Women